Geron Corporation Securities Fraud Allegations: An Opportunity for Investors to Take Action
In the bustling metropolis of Los Angeles, the financial world has been abuzz with the latest securities fraud lawsuit against Geron Corporation (NASDAQ: GERN). The Schall Law Firm, a renowned securities class action law firm, has announced that investors who purchased Geron Corporation securities between February 28, 2019, and November 18, 2019, inclusive, may be entitled to join a class-action lawsuit against the company.
What is the Allegation?
According to the complaint filed in the United States District Court for the Northern District of California, Geron Corporation and certain of its executives allegedly made false and misleading statements to the market regarding the company’s business, operations, and financial condition.
Details of the Allegations
The complaint alleges that Geron Corporation failed to disclose adverse clinical trial data for its investigational therapy, imetelstat, which is being developed for the treatment of myelofibrosis and beta-thalassemia. Specifically, the complaint alleges that the company and its executives failed to disclose that the clinical trial data showed that imetelstat failed to meet the primary endpoint in the pivotal Phase 3 trial for myelofibrosis.
Impact on Geron Corporation
The allegations have sent shockwaves through the investment community, leading to significant volatility in Geron Corporation’s stock price. Following the announcement of the securities fraud lawsuit, Geron Corporation’s stock price plummeted, causing losses for many investors.
Impact on Individual Investors
If you are an individual investor who purchased Geron Corporation securities between February 28, 2019, and November 18, 2019, you may be entitled to join the class-action lawsuit against the company. The Schall Law Firm is actively investigating the role of Geron Corporation’s executives in the alleged securities fraud. If you have suffered losses, you are encouraged to contact the firm as soon as possible.
Implications for the Biotech Industry
The Geron Corporation securities fraud allegations have raised concerns about the transparency and integrity of the biotech industry as a whole. The incident serves as a reminder that investors must remain diligent in their research and due diligence when investing in biotech companies, particularly those with promising but unproven therapies.
Conclusion
The securities fraud allegations against Geron Corporation represent an opportunity for investors who have suffered losses to take action and seek justice. The Schall Law Firm is dedicated to holding Geron Corporation and its executives accountable for any misrepresentations or false statements made to the market. As the investigation progresses, it is essential for investors to stay informed and vigilant, ensuring that the biotech industry remains transparent and trustworthy.
- Geron Corporation Securities Fraud Allegations: An Opportunity for Investors to Take Action
- Schall Law Firm Announces Securities Class Action Lawsuit Against Geron Corporation
- Geron Corporation Faces Securities Fraud Lawsuit over Alleged Misrepresentations
